ArticleJournal of diabetes and metabolic disorders2025
The multifaceted modulations by dapagliflozin in preventing hyperglycemia-induced diabetic nephropathy through glucose transporters and PPARα.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diabetic nephropathy (DN) contributes to the higher mortality, and Forxiga (dapagliflozin) effectively improves clinical outcomes of patients with type 2 diabetes. However, the effects of dapagliflozin on hyperglycemia-induced DN remain unclear. Methods: Streptozotocin (STZ)-induced diabetic rats were used to investigate hyperglycemia-induced DN, and various parameters were evaluated for the oral administration of dapagliflozin (1.2 mg/kg/day) for 12 weeks in STZ-induced diabetic rats, including serum metabolic parameters, kidney morphology, renal glycogen, and renal collagen. Additionally, the biomedical mechanisms were further assessed by western blotting and immunohistochemistry staining. Results: Compared to normal rats, we observed significant changes in STZ-induced diabetic rats for metabolic parameters, renal pathogenesis, glycogen deposition, and collagen accumulation. However, the treatment with dapagliflozin for 12 weeks in STZ-induced diabetic rats significantly increased body weight, decreased plasma glucose, triglyceride, cholesterol, creatinine and blood urea nitrogen levels, and improved renal pathology, glycogen deposition, and collagen accumulation compared with STZ-induced diabetic rats. Additionally, hyperglycemia-induced DN further elevated renal expressions of N-cadherin, yes-associated protein (YAP), fibronectin, Myosin IIB, alpha-smooth muscle actin (α-SMA), CD11b, tumor necrosis factor alpha (TNF-α), caspase-3, acetyl superoxide dismutase 2 (AcSOD2) involved in renal epithelial-to-mesenchymal transition (EMT), fibrosis, inflammation, apoptosis, and oxidative stress, which were attenuated by dapagliflozin. Moreover, the higher expressions of renal glucose transporter 2 (GLUT2) and GLUT4, and lower expressions of renal peroxisome proliferator-activated receptor α (PPARα) in STZ-induced diabetic rats were reversed by dapagliflozin. Conclusions: Dapagliflozin in STZ-induced diabetic rats exhibited anti-inflammation, anti-oxidation, EMT modulation, anti-apoptosis, and anti-fibrosis through the mediation of renal GLUT2, GLUT4, and PPARα expressions in the prevention of hyperglycemia-induced DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.